Xaira Therapeutics
Xaira Therapeutics raises $1B Series A at $4B valuation
Quick Facts
Xaira Therapeutics: Series A Funding Round
Xaira Therapeutics has successfully raised $1B in Series A funding, reaching a valuation of $4B.
Company Overview
AI-powered drug discovery platform
Funding Details
The Series A round was led by Foresite Capital, with participation from ARCH Venture Partners, NEA.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2023
- Employees: 100+
- Category: Biotech
Investment
Xaira Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series A
- ARCH Venture Partners: Verified investor in Series A
- NEA: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
